Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$38.33 USD
+1.09 (2.93%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $38.28 -0.05 (-0.13%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APGE 38.33 +1.09(2.93%)
Will APGE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Other News for APGE
BTIG Increases Price Target for Apogee Therapeutics (APGE) to $115 | APGE Stock News
Apogee Therapeutics price target raised by $15 at BTIG, here's why
Gold Falls 1%; ProKidney Shares Spike Higher
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
12 Health Care Stocks Moving In Monday's Intraday Session